Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: A multicenter, open-labeled, three-armed study

Basit Öğe Kaydı
dc.contributor.authorKoylan, N
dc.contributor.authorAcarturk, E
dc.contributor.authorCanberk, A
dc.contributor.authorCaglar, N
dc.contributor.authorCaglar, S
dc.contributor.authorErdine, S
dc.contributor.authorGuneri, S
dc.contributor.authorIlerigelen, B
dc.contributor.authorKabakci, G
dc.contributor.authorOnder, R
dc.contributor.authorSagkan, O
dc.contributor.authorBuyukozturk, K
dc.date.accessioned2019-10-27T19:24:24Z
dc.date.available2019-10-27T19:24:24Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives. This multicenter, three-armed, open-labeled study investigated patient compliance of patients receiving irbesartan, angiotensin-converting enzyme (ACE) inhibitors or calcium-channel blockers (CCB) for essential hypertension for a 6-month period. Patients were either newly diagnosed or switched from existing antiltypertensive medication due to lack of efficacy or side-effects. Methods. Patients were started monotherapy with irbesartan (n=377), ACE inhibitors (n=298) or CCB (n=308) and were reevaluated on 1st, 3rd, and 6th months of the treatment. The primary endpoint was patient compliance, assessed by proportion of patients who had taken their study medication every day. Efficacy was recorded as mean reductions in blood pressure and the proportion of patients whose blood pressure normalized. Tolerability was assessed by reported adverse events. Results. Significantly more patients receiving irbesartan had complied with study medication after 3 and 6 months of treatment than ACE inhibitors or CCB. Significantly fewer patients receiving irbesartan needed to change their antihypertensive medication. All three study treatments exhibited similar efficacy profiles, but irbesartan had significantly less adverse events. Conclusions. This study demonstrated that patient compliance to irbesartan was significantly superior to other study treatments. Irbesartan is therefore a suitable first-line therapy for essential hypertension in everyday clinical practice.en_US
dc.identifier.doi10.1080/08038020510040649en_US
dc.identifier.endpage31en_US
dc.identifier.issn1651-1999
dc.identifier.pmid16060413en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage23en_US
dc.identifier.urihttps://doi.org/10.1080/08038020510040649
dc.identifier.urihttps://hdl.handle.net/11454/39270
dc.identifier.volume14en_US
dc.identifier.wosWOS:000230898400004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBlood Pressureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectACE inhibitorsen_US
dc.subjectangiotensin II receptor antagonistsen_US
dc.subjectcalcium-channel blockersen_US
dc.subjectcomplianceen_US
dc.subjectessential hypertensionen_US
dc.subjectirbesartanen_US
dc.titleEffect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: A multicenter, open-labeled, three-armed studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu